NYXOAH S A Stock Price, News & Analysis

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from BlackRock, Inc. on December 19, 2024. The notification reveals that BlackRock and its controlled undertakings now hold 1,124,630 voting rights in Nyxoah, comprising 1,122,658 shares and 1,972 equivalent financial instruments. This represents 3.00% of the total voting rights (37,427,265) as of December 17, 2024.

The holdings are distributed across various BlackRock entities, with BlackRock Advisors, holding the largest portion at 2.91% of voting rights. The notification was triggered by BlackRock's total holdings crossing above the 3% threshold.

Nyxoah has launched its Genio system commercially in England, with the first successful implants performed at University College London Hospitals (UCLH). The system, which treats Obstructive Sleep Apnea (OSA) through neuromodulation, is now covered under the NHS Specialised Services Devices Programme (SSDP). The first two patients received their implants from Mr. Ryan Chin Taw Cheong, Consultant ENT and Sleep Surgeon at UCLH. This launch marks a significant expansion of Nyxoah's innovative OSA treatment in the UK healthcare market.

Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its voting rights and shares as required by Belgian law. The company reports a share capital of EUR 6,429,682.56 with 37,427,265 ordinary shares, each carrying one voting right. Additionally, there are 2,296,194 subscription rights to securities not yet issued, excluding 346,431 subscription rights that were issued but not yet granted.

Nyxoah (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on developing innovative Obstructive Sleep Apnea (OSA) treatments through neuromodulation, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will deliver a presentation on Wednesday, December 4, 2024, at 2:00pm ET.

Interested parties can access a live audio webcast of the presentation through the investor relations section of Nyxoah's website at investors.nyxoah.com.

Nyxoah SA announces a special shareholders' meeting scheduled for December 19, 2024, at 3:00 p.m. CET at the company's headquarters. The meeting will address the approval of clauses in the EIB Agreements, including a loan facility and synthetic warrant agreement with the European Investment Bank. Key points include Change-of-Control Event provisions and voting procedures.

Shareholders can participate in person or via video conference, with voting available through mail or proxy before December 13, 2024. Registration date is set for December 5, 2024. The meeting requires no specific quorum, and decisions will be adopted by simple majority vote. Each share entitles one vote.

Nyxoah SA announced receiving a transparency notification from ResMed Inc. regarding a passive threshold crossing. According to the notification dated November 5, 2024, ResMed Inc. now holds 1,727,864 voting rights, representing 4.62% of the total voting rights (37,389,015) as of October 9, 2024. This represents a decrease below the 5% threshold. ResMed Inc. is not a controlled entity and holds these voting rights directly without any indirect holdings.

Nyxoah reported third quarter 2024 financial results with revenue of €1.3 million, representing 30% growth versus Q3 2023. The company's total cash position reached €71.0 million at quarter-end, with an additional €24.6 million raised through an ATM program. Operating loss increased to €15.0 million from €11.0 million in Q3 2023. Research and development expenses were €7.9 million, up from €6.6 million year-over-year. The company remains on track for FDA approval in Q1 2025 and is building its U.S. commercial team, with cash runway extended until mid-2026.

Nyxoah has appointed John Landry as its new Chief Financial Officer, effective November 4, 2024. This appointment, along with CEO Olivier Taelman's recent move to the United States, reinforces the company's focus on the U.S. market. Landry brings over 20 years of financial leadership experience in healthcare and medtech, previously serving as CFO at Vapotherm Inc. Current CFO Loïc Moreau will transition to the newly created role of President International, where he will lead Nyxoah's global expansion efforts.

Nyxoah SA announced receiving a transparency notification from Vestal Point Capital following changes in voting securities. According to the notification dated October 22, 2024, Vestal Point Capital now holds 3,000,688 voting rights, representing 8.03% of total voting rights (37,389,015) as of October 9, 2024. The threshold of 5% was crossed. Vestal Point Capital, LP is controlled by Vestal Point Capital, (general partner), which is controlled by Ryan Wilder (managing member). Vestal Point Capital, LP serves as the investment management company with discretionary voting rights.